Systematic Aetiological Assessment of Myocarditis: A Prospective Cohort Study
- PMID: 38398340
- PMCID: PMC10889734
- DOI: 10.3390/jcm13041025
Systematic Aetiological Assessment of Myocarditis: A Prospective Cohort Study
Abstract
Background: Myocarditis is commonly diagnosed in the intensive care cardiology unit (ICCU). No current recommendation nor guideline aids exist for aetiological assessments.
Methods: From September 2021 to October 2023, 84 patients with acute myocarditis underwent thorough and systematic serum and blood cell panel evaluations to determine the most common causes of myocarditis.
Results: Of the 84 patients (median age 34 years, range 22-41 years, 79% male), 16 presented with complicated myocarditis. The systematic aetiological assessment revealed that 36% of patients were positive for lupus anticoagulant, 12% for antinuclear antibodies, 8% for anti-heart antibodies, and 12% for anti-striated muscle antibodies. Viral serology did not yield any significant results. After the aetiological assessment, one patient was diagnosed with an autoimmune inflammatory disorder (Still's disease). T-cell subset analyses indicated that myocarditis severity tended to increase with the T-cell lymphopenia status.
Conclusions: A comprehensive, systematic aetiological assessment was of limited value in terms of predicting the clinical or therapeutic outcomes in myocarditis patients presenting to the ICCU.
Keywords: aetiological assessment; autoimmune and inflammatory disorders; myocarditis.
Conflict of interest statement
Edouard Gerbaud is a consultant for Terumo and Abbott Vascular. Edouard Gerbaud reports personal fees from Vifor Pharma Group and Servier. Vincent Michel, Thomas Fauthoux, Thomas Baudinet, Cécile Contin-Bordes, Patrick Blanco and Estibaliz Lazaro report no conflicts of interest. Laura Cetran reports consulting fees from Vifor Pharma Group and Abbott Vascular. Benjamin Seguy reports speaker fees from Bayer. Pierre Coste reports personal fees from Amgen, Sanofi, Servier, AstraZeneca, Vifor Pharma Group and Abiomed.
References
-
- Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
-
- Ferreira V.M., Schulz-Menger J., Holmvang G., Kramer C.M., Carbone I., Sechtem U., Kindermann I., Gutberlet M., Cooper L.T., Liu P., et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation. J. Am. Coll. Cardiol. 2018;72:3158–3176. doi: 10.1016/j.jacc.2018.09.072. - DOI - PubMed
-
- Ammirati E., Frigerio M., Adler E.D., Basso C., Birnie D.H., Brambatti M., Friedrich M.G., Klingel K., Lehtonen J., Moslehi J.J., et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ. Heart Fail. 2020;13:e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
